US Bancorp DE Trims Stake in Medpace Holdings, Inc. $MEDP

US Bancorp DE cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,535 shares of the company’s stock after selling 853 shares during the quarter. US Bancorp DE’s holdings in Medpace were worth $2,051,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group increased its position in shares of Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. increased its position in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Medpace during the first quarter worth approximately $60,000. Finally, Assetmark Inc. increased its position in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after acquiring an additional 43 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent research reports. Jefferies Financial Group increased their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Rothschild Redb downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Cowen downgraded shares of Medpace from a “buy” rating to a “sell” rating in a research note on Wednesday, July 23rd. Robert W. Baird increased their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Finally, William Blair reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $424.10.

Insider Activity

In related news, President Jesse J. Geiger sold 41,801 shares of the business’s stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the completion of the transaction, the president directly owned 36,503 shares in the company, valued at $16,539,874.33. The trade was a 53.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Susan E. Burwig sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the transaction, the vice president owned 57,500 shares of the company’s stock, valued at $27,600,000. This represents a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 161,266 shares of company stock valued at $74,111,427 over the last quarter. Insiders own 20.30% of the company’s stock.

Medpace Trading Down 0.5%

NASDAQ:MEDP opened at $514.32 on Thursday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $547.15. The firm has a fifty day simple moving average of $488.51 and a 200-day simple moving average of $378.75. The company has a market capitalization of $14.45 billion, a P/E ratio of 38.24, a PEG ratio of 3.24 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the firm posted $2.75 earnings per share. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.